Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of ZMapp in Healthy Volunteers
NCT02389192Phase 1Withdrawn
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2015
- Primary completion
- Dec 2017
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, open-label, single-arm trial of ZMapp in Ebola virus disease (EVD), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Safety of a single IV infusion of 50 mg/kg of ZMappTM at Day 90 and Serum pharmacokinetics at Day 90. Planned start Mar 2015; status: withdrawn.
02
Drugs
ZMapp
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT02389192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02389192.